We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > FGFR

News List

Oncology biotech Tyra Biosciences files for a $100 million IPO firstwordpharma
August 23, 2021
Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital.
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer drugs
April 17, 2019
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer.
Qiagen launches first FGFR-based cancer diagnostic fiercebiotech
April 17, 2019
Alongside Janssen’s accelerated approval of Balversa as the first targeted therapy for metastatic bladder cancer, the FDA also greenlighted Qiagen’s companion diagnostic test to ...